Elevation Oncology Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Elevation OncologyDer Gewinn des Unternehmens wird voraussichtlich um 16.5% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 87% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich zurückgehen.

Wichtige Informationen

-16.5%

Wachstumsrate der Gewinne

-0.1%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.3%
Wachstumsrate der Einnahmen	87.0%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	07 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Companies Like Elevation Oncology (NASDAQ:ELEV) Are In A Position To Invest In Growth

Sep 25

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:ELEV - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-88	-93	-117	5
12/31/2025	N/A	-63	-81	-53	7
12/31/2024	N/A	-48	-42	-39	7
9/30/2024	N/A	-42	-38	-38	N/A
6/30/2024	N/A	-40	-43	-43	N/A
3/31/2024	N/A	-39	-49	-49	N/A
12/31/2023	N/A	-46	-56	-56	N/A
9/30/2023	N/A	-57	-62	-62	N/A
6/30/2023	N/A	-85	-93	-93	N/A
3/31/2023	N/A	-95	-88	-88	N/A
12/31/2022	N/A	-95	-86	-85	N/A
9/30/2022	N/A	-86	-77	-77	N/A
6/30/2022	N/A	-59	-40	-40	N/A
3/31/2022	N/A	-44	-35	-35	N/A
12/31/2021	N/A	-32	-30	-30	N/A
9/30/2021	N/A	-31	-25	-25	N/A
6/30/2021	N/A	-22	-22	-21	N/A
3/31/2021	N/A	-20	-20	-20	N/A
12/31/2020	N/A	-17	-12	-12	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ELEV wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ELEV wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ELEV wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ELEV wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: ELEV wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ELEV in 3 Jahren voraussichtlich hoch sein wird

Elevation Oncology Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 8.2% to US$7.50

Price target increased by 24% to US$6.00

Price target decreased by 19% to US$4.17

Price target decreased to US$5.17

Recent updates

Price target decreased by 8.2% to US$7.50

Elevation Oncology Receives Non-Compliance Letter Regarding Nasdaq Minimum Bid Price Requirement

New minor risk - Market cap size

Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2

Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer

Elevation Oncology: Mid-2024 EO-3021 Data Could Get Ball Rolling

Elevation Oncology, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Elevation Oncology, Inc., Annual General Meeting, Jun 13, 2024

Elevation Oncology, Inc. Appoints Julie Cherrington and Alan Sandler to Board of Directors

Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan

Elevation Oncology Announces Appointment of Darcy Mootz to Its Board of Directors and as Member of the Compensation Committee

Elevation Oncology Announces Appointment of Darcy Mootz to Its Board of Directors

Elevation Oncology: Rising On News, But Not The Time To Buy

Elevation Oncology, Inc. Plans to Provide an Update from Its Ongoing Phase 1 Trial of EO-3021

New minor risk - Share price stability

Elevation Oncology Receives Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

Elevation Oncology Receives Notice from the Listing Qualifications Staff of the Nasdaq Stock Market

Elevation Oncology, Inc. Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating E)-3021

Elevation Oncology, Inc Appoints Joseph J. Ferra, Jr. as Chief Executive Officer

New major risk - Financial position

New major risk - Shareholder dilution

Elevation Oncology, Inc. has completed a Follow-on Equity Offering in the amount of $50.062056 million.

Elevation Oncology Inc. Together with CSPC Pharmaceutical Group Limited Announce Promising Initial Clinical Data for SYSA1801 (EO-3021) from the Ongoing Phase 1 Dose Escalation and Expansion Study in China

Price target increased by 24% to US$6.00

Advisor notifies of intention to sell stock

Advisor notifies of intention to sell stock

Price target decreased by 19% to US$4.17

Elevation Oncology, Inc. Announces Management Changes

Price target decreased to US$5.17

Elevation Oncology GAAP EPS of -$0.86 misses by $0.07

Elevation Oncology secured $50M loan facility with K2 HealthVentures

Now 36% undervalued after recent price drop

Elevation Oncology to Present Initial Seribantumab Proof-of-Concept Data from Phase 2 CRESTONE Study in Patients with Tumors Harboring NRG1 Fusions at ASCO 2022

We're Hopeful That Elevation Oncology (NASDAQ:ELEV) Will Use Its Cash Wisely

Elevation Oncology, Inc. Appoints David Dornan as Chief Scientific Officer

Elevation Oncology, Inc., Annual General Meeting, Jun 17, 2022

Elevation Oncology, Inc. Announces Initial Data from Phase 2 CRESTONE Study of Seribantumab Selected for Oral Presentation at ASCO 2022

Less than half of directors are independent

We're Not Very Worried About Elevation Oncology's (NASDAQ:ELEV) Cash Burn Rate

Companies Like Elevation Oncology (NASDAQ:ELEV) Are In A Position To Invest In Growth

Elevation Oncology, Inc. has completed an IPO in the amount of $100 million.

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken